(2)期间费用影响。报告期内，公司坚持创新驱动发展战略和团队激励建设，聚焦POCT产品的深度研发 与品质提升，推出满足不同细分领域和客户个性化需求的高质量产品，持续推进品牌建设和渠道推广， 研发费用、员工持股计划产生的股份支付费用增加，此外，汇率波动、金融市场存款利率下行导致的财 务性收益同比减少。以上导致利润下滑显著。 (3)非经营性损益的影响。上期受境外客户在新冠疫情期间的病毒检测产品订单于2024年度终止影响， 无需返还的500万美元订单预收款及代收运输费在2024年度转为收入，导致2024年净利润增加。报告期 内，公司未发生此类收入。 格隆汇2月27日丨博拓生物(688767.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入4.48亿 元，较上年同期减少19.85%；营业利润5005.38万元，较上年同期减少74.12%；归属于母公司所有者的 净利润4679.57万元，较上年同期减少72.39%；归属于母公司所有者的扣除非经常性损益的净利润 2498.15万元，较上年同期减少79.06%。 影响经营业绩的主要因素： (1)营业收入影响。2025年上半年，由于美国政府多次加征关税引发市场重大 ...

博拓生物晚间公告，2025年度营业总收入4.48亿元，同比下降19.85%；净利润4679.57万元，同比下降 72.39%。2025年上半年，由于美国政府多次加征关税引发市场重大波动，公司对美出口销售下滑；受 行业竞争加剧及部分传染病检测市场周期性波动影响，国内呼吸道检测产品以及拉美地区登革热等蚊媒 类产品销售收入同比减少。 ...

Core Viewpoint - 博拓生物 reported a significant decline in both revenue and net profit for the first half of 2025, primarily due to external factors such as tariffs and reduced demand for certain products [1] Financial Performance - The company achieved an operating revenue of 203 million yuan, representing a year-on-year decrease of 23.91% [1] - The net profit attributable to shareholders was 12.4 million yuan, down 82.82% year-on-year [1] - Basic earnings per share were reported at 0.07 yuan [1] Factors Affecting Performance - Revenue from the U.S. market decreased due to the impact of tariffs and a slowdown in government procurement [1] - Domestic demand for respiratory testing products declined due to cyclical fluctuations, while demand for dengue fever and other mosquito-borne products in Latin America also decreased [1] - Increased registration fees and share-based payment expenses from employee stock ownership plans contributed to the financial strain, alongside reduced foreign exchange gains and interest income [1]